（文章来源：证券时报网） 据Wind统计，截至1月20日，沪深两市共有142只个股连续5日或5日以上获主力资金净买入。连续获主 力资金净买入天数最多的股票是锋龙股份，已连续15个交易日获净买入；连续获主力资金净买入天数较 多的还有安徽合力、*ST国化、康辰药业、九鼎投资、陕西煤业、伊利股份、微电生理、赣粤高速等 股。 ...

Core Viewpoint - As of January 19, a total of 144 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Fenglong Co., which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Anhui Heli, Shanghai Airport, Yong'an Forestry, *ST Guohua, Neway Group, Kangchen Pharmaceutical, Shentong Metro, and Qibin Group [1]

近日，北京康辰药业股份有限公司（证券简称：康辰药业，证券代码：603590.SH）发布业绩预 告，随着2024年商誉减值准备计提影响的消退，2025年归母净利润预计同比大增243%至315%。需要注 意的是，净利大增的核心逻辑是低基数修复。而在业绩预增的光环之下，公司不仅未能根治营收结构单 一的问题，还需面对股东减持余波与新品研发失败风险，长期发展不确定性仍高。 新品研发终止 为了解决单品依赖的问题，近年来，康辰药业不断加大创新药的研发。但由于战略或技术误判，导 致多起新品研发失败或终止。 单品依赖隐忧仍存 2026年1月8日，康辰药业发布业绩预告，预计2025年年度实现归母净利润为14500万元到17500万 元，同比增加10278.33万元到13278.33万元，同比增加243%到315%。公司预计2025年年度实现归母扣 非净利润为14000万元到17000万元，同比增加10892.32万元到13892.32万元，同比增加350%到447%。 对于业绩预增的原因，康辰药业称，2024年，公司根据企业会计准则对收购原泰凌医药国际有限公 司（现更名：方恒医药国际有限公司）股权所形成的商誉计提商誉减值准备导致 ...

Core Insights - Approximately 130 A-share companies have disclosed their performance forecasts for 2025, with around 70 companies expecting positive results, including profit increases and turnaround from losses [2][4]. Company Performance Highlights - **Zhongke Lanyun**: Expected net profit of 1.4 billion to 1.43 billion yuan, a year-on-year increase of 366.51% to 376.51%, driven by strategic investments in high-growth areas like GPU and advanced packaging [4][5]. - **Chuanhua Zhili**: Forecasted net profit of 540 million to 700 million yuan, with a growth rate of 256.07% to 361.57%, supported by optimized marketing strategies and asset structure in logistics and chemical businesses [5]. - **Bai'ao Saitou**: Anticipated net profit of 135 million yuan, reflecting a 303.57% increase, attributed to favorable market conditions [4]. - **Kangchen Pharmaceutical**: Expected net profit of 145 million to 175 million yuan, with a growth of 243% to 315%, due to the absence of goodwill impairment losses in the reporting period [5]. - **Guangku Technology**: Projected net profit of 169 million to 182 million yuan, a growth of 152% to 172%, driven by product innovation and cost control [7]. - **Lixun Precision**: Forecasted net profit of 16.518 billion to 17.186 billion yuan, with a growth of 23.59% to 28.59%, supported by innovations in manufacturing and AI integration [6]. - **Daotong Technology**: Expected net profit of 900 million to 930 million yuan, with a growth of 40.42% to 45.10%, driven by AI-driven services [6]. - **Aibisen**: Anticipated net profit of 240 million to 290 million yuan, reflecting a growth of 105.32% to 148.09%, due to increased R&D investment [7]. - **Chaohongji**: Expected net profit of 436 million to 533 million yuan, with a growth of 125% to 175%, supported by a focus on brand optimization and digital transformation [9]. - **WuXi AppTec**: Forecasted net profit of 19.151 billion yuan, with a growth of approximately 102.65%, including gains from divesting joint ventures [9]. - **Hui Sheng Biological**: Expected net profit of 23.5 million to 27.1 million yuan, indicating a turnaround, driven by market expansion and improved production efficiency [9]. Industry Performance Insights - The electronics, semiconductor, pharmaceutical, and machinery sectors are showing strong performance among listed companies [3].

Core Viewpoint - The A-share annual report season is progressing, with 87 companies releasing their 2025 annual performance forecasts, leading to significant stock price movements, including a limit-up for Nanxing Co., Ltd. [1] Group 1: Company Performance Forecasts - 17 companies, including Zhongke Lanyun, Chuanhua Zhili, Kangchen Pharmaceutical, and others, are expected to see a year-on-year increase in net profit exceeding 100% [1] - Zhongke Lanyun leads with an anticipated net profit of 1.4 billion to 1.43 billion yuan, reflecting a growth of 366.51% to 376.51% compared to the previous year, primarily due to significant gains from investments [1] - Chuanhua Zhili forecasts a net profit of 540 million to 700 million yuan, representing a growth of 256.07% to 361.57%, driven by optimized marketing strategies and asset structure in its logistics business [2] - Kangchen Pharmaceutical expects a net profit of 145 million to 175 million yuan, an increase of 243% to 315%, with no impact from goodwill impairment in the current reporting period [2] Group 2: Specific Company Highlights - Nanxing Co., Ltd. projects a net profit of 90 million to 120 million yuan for 2025, recovering from a loss of 175 million yuan in the previous year, attributed to reduced goodwill impairment impact and growth in its IDC business [3]

Core Viewpoint - Kangchen Pharmaceutical is currently focusing on the domestic market, with export business accounting for a small proportion of overall revenue. However, international expansion is a crucial part of the company's "ten-year strategy" as it aims to align with the trend of integration between the Chinese and international pharmaceutical markets [2]. Group 1 - The company emphasizes that its business is primarily concentrated in the domestic market, with a minor share of revenue coming from exports [2]. - Kangchen Pharmaceutical views international expansion as an essential path for innovative enterprises, indicating a commitment to enhancing its research and development pipeline [2]. - The company plans to actively promote its international strategic layout in response to the growing integration of the Chinese market with the global pharmaceutical market [2].

Group 1 - Insilico Medicine announced a collaboration with Servier valued at $888 million focused on the discovery and development of innovative anti-cancer therapies [1] - Insilico will receive up to $32 million in upfront and milestone payments, leveraging its AI-driven drug development platform [1] - Servier will lead the clinical validation and commercialization of promising drug candidates globally [1] Group 2 - Weigao Blood Products announced a major asset restructuring involving the acquisition of 100% equity in Weigao Purui for approximately $8.511 billion [2] - Post-transaction, Weigao Purui will become a wholly-owned subsidiary, expanding the company's business into pharmaceutical packaging [2] - Weigao's shareholding in Weigao Blood Products will increase to 84.36%, maintaining absolute control [2] Group 3 - Earendil Labs (HuaShen ZhiYao) entered a strategic partnership with Sanofi worth up to $2.56 billion for the development of bispecific candidates targeting autoimmune and inflammatory diseases [3] - Earendil Labs will receive up to $160 million in upfront and milestone payments linked to early project outcomes [3] - The agreement includes tiered royalties based on net sales [3] Group 4 - WuXi AppTec announced that its controlling shareholders have reduced their stake by 2%, totaling 59.68 million shares [4] - The reduction was completed as per the previously disclosed plan, with the controlling shareholders holding 18.211% of the total shares before the reduction [4] Group 5 - Nanhua Biological announced plans for a significant asset restructuring to acquire 51% of Huize Pharmaceutical for cash [5] - The transaction is expected to constitute a major asset restructuring without involving share issuance or control changes [5] - Due diligence and negotiations are ongoing, with no formal agreement signed yet [5] Group 6 - Kangchen Pharmaceutical projected a net profit of between 145 million to 175 million yuan for 2025, representing a year-on-year increase of 243% to 315% [6] - The expected net profit excluding non-recurring gains is projected to be between 140 million to 170 million yuan, reflecting a significant increase from the previous year [6] Group 7 - Yilian Biotech signed a new exclusive licensing agreement with Roche for the YL201 project, with an upfront payment of $570 million [7] - The agreement allows Roche exclusive rights to develop and commercialize the YL201 project globally, excluding mainland China and certain regions [7] - This partnership builds on a successful collaboration on the YL211 project, aiming to accelerate the development of YL201 [7]

Core Insights - A total of 74 companies have released their annual performance forecasts, with 58 companies expecting profit increases, representing 78.38% of the total [1] - The overall proportion of companies forecasting positive results is 83.78%, with 4 companies expecting profits and 7 companies anticipating losses [1] - Among the companies predicting profit increases, 18 are expected to see net profit growth exceeding 100%, while 13 companies forecast growth between 50% and 100% [1] Company Performance - Zhongtai Co. is projected to have the highest net profit growth at 677.22%, followed by Zhongke Lanyun at 371.51% and Chuanhua Zhili at 308.82% [1][2] - The average increase in stock prices for companies expecting profit growth has been 10.46% this year, outperforming the Shanghai Composite Index [1] - The best-performing stock this year is Beifang Navigation, with a cumulative increase of 36.64% [1] Industry Insights - Companies expecting to double their profits are primarily concentrated in the electronics, pharmaceutical, and basic chemical industries, with 3, 2, and 2 companies respectively [1] - In terms of market segments, the companies expecting profit growth are distributed across the main board (11 companies), the ChiNext board (5 companies), and the Sci-Tech Innovation board (2 companies) [1]

证券之星消息，1月8日生物制品板块较上一交易日上涨0.58%，康辰药业领涨。当日上证指数报收于 4082.98，下跌0.07%。深证成指报收于13959.48，下跌0.51%。生物制品板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300009 | 安科生物 | 5765.57万 | 17.68% | -2259.90万 | -6.93% | -3505.67万 | -10.75% | | 603590 | 康辰药业 | 5207.13万 | 11.50% | 2603.96万 | 5.75% | -7811.09万 | -17.25% | | 000661 | 长春高新 | 3760.20万 | 4.73% | -2231.56万 | -2.80% | -1528.64万 | -1.92% | | 000403 派林生物 | | 2447.38万 | 10.57% | -748.68万 | ...

康辰药业股价出现异动，截至今日11时28分，股价大涨5.37%，成交613.10万股，成交金额2.64亿元， 换手率为3.87%，公司发布的最新业绩预告显示，预计2025年实现净利润1.45亿元—1.75亿元，净利润 同比增长243.00%—315.00%。 证券时报·数据宝统计显示，今日公布2025年业绩预告公司中，截至发稿股价较为强势的有川金诺、高 能环境、中科蓝讯等，股价分别上涨9.75%、9.54%、9.36%。 资金面上看，康辰药业近5日主力资金总体呈净流入状态，累计净流入556.94万元，其中，上一交易日 主力资金全天净流入540.20万元。（数据宝） （文章来源：证券时报网） ...